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HLA allele.
The pool of CTL donors inherited HLA alleles in frequencies
similar to those in caucasian and black populations, with
certain alleles overrepresented. In 55% of the CTL lines, the ID
T-cell response (TCr) was restricted (restr.) by 3 HLA alleles:
A0201(25%), B0702(21%) and B 3501-11(9%); 45% of CTL lines
were restr. by other class-I alleles, and 17/123(14%) were
restr. by class-II alleles. Certain CMVpp65 15 mers contained
overlapping eps presented by both class-I and class-II, which
elicitedmore robust TCr. CTLs from all B0702+ donors (26/26)
were restr. by B0702. In comparison, CTLs from 30/39(77%)
A0201+ donors and 9/19 (47%) HLA B3501-11+ donors were
restr. by A0201 and B3501-11 respectively. Donors co-
inheriting A0201 and B 0702 (9/9) universally demonstrated
B0702 restr. ID TCr. In comparison, 11/12 (91.6%) donors co-
inheriting A0201 and B 4401-04 demonstrated HLA A0201
restr. CTLs. Strikingly, only 1/123 and 0/123 A1101+ and
A0301+ donors respectively demonstrated CTLs restr. by
these commonly inherited class eI alleles. This analysis thus
indicates an immunodominance hierarchy for CMVpp65 eps
and their presenting HLA alleles. In a series of 239 MUD, 137
MMUD, and 100 DUCB consecutive HSCT at MSKCC, we could
identify an immediately available CMVpp65 speciﬁc CTL line
matched with the patient at 2-3 alleles and restr. by a shared
HLA allele in this GMP-CTL bank in 86%, 89% and 80% cases
respectively. This CTL bank thus provides a clinical reagent
for the treatment of CMV infections in HSCT recipients. The
delineated immunodominance hierarchy for CMVpp65 may
also facilitate selection of an appropriately restr. CTL line for
treatment with predicted activity in the recipient. We can
also successfully generate CMV-CTLs against subdominant
CMVpp65 eps presented prevalent HLA alleles using a panel
of artiﬁcial antigen presenting cells (AAPCs). Expansion of
this bank with CTLs generated with AAPCs can broaden its
applicability to almost all HSCT recipients.180
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Lymphodepletion before adoptive cell transfer (ACT) can
enhance anti-tumor responses by increasing access to ho-
meostatic cytokines and by depressing the numbers of reg-
ulatory cells. However, the lymphodepleted recipient is at
risk for morbidity and mortality from pathogens. Indeed,
opportunistic invasive fungal infection (IFI) by Aspergillus sp.
results in a 60 to 85% in patients undergoing hematopoietic
stem-cell transplantation. Antifungal agents such as poly-
enes, triazoles, and echinocandins can be rendered ineffec-
tive due to shifts in fungal epidemiology, emergence of drug
resistant strains, and attendant toxicities in the recipients.
Thus, other strategies are being developed that target fungi.
Clinical-grade T cells genetically modiﬁed to express
chimeric antigen receptors (CARs) have been successfully
used to redirect speciﬁcity to target tumor-associated anti-
gens. We and others have infused CD19-speciﬁc T cells inpatients undergoing HSCT for investigational treatment of B-
cell malignancies. This provides a platform to expand the role
of adoptive immunotherapy to also target IFI.We adapted the
pattern-recognition receptor Dectin-1 to activate T cells via
chimeric CD28 and CD3-z (designated D-CAR) upon binding
with carbohydrate cell wall in Aspergillus germlings. The D-
CAR+ T cells exhibited speciﬁcity for b-1,3-gucan and
inhibited hyphal growth of Aspergillus. The D-CAR was then
expressed with our CD19-speciﬁc CAR (designated
CD19RCD28) which is currently used in clinical trials. Our
existing manufacturing platform was readily adapted to
electro-transfer plasmids from the Sleeping Beauty (SB) sys-
tem. Clinical-grade CD19-speciﬁc CAR+ T cells are produced
after introducing two DNA plasmids coding for transposon
(CD19RCD28) and transposase (SB11). The synchronous
electro-transfer of a third SB-derived DNA plasmid coding for
D-CAR resulted in CD19RCD28+D-CAR+ T cells. The resultant
genetically modiﬁed T cells can target both CD19+ malignant
B cells and Aspergillus. Generating CD19-speciﬁc T cells with
multiple speciﬁcities will enable introduced fungal immu-
nity to be long-lived and provides a foundation for engi-
neering an immune response with that can target multiple
antigens, such as to prevent the emergence of antigen-
escape variants.181
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Adoptive transfer of ag speciﬁc T-cells can effectively eradi-
cate viral infections and tumors. T-cells can be targeted to
speciﬁc ags expressed on tumor cells by genetic modiﬁcation
to express chimeric ag receptors (CARs); which are fusion
proteins incorporating an ag recognition moiety (ab) and T-
cell activation domains. Human T-cells genetically modiﬁed
to express a CD19-targeted CAR have been demonstrated to
successfully eradicate CD19+ B cell malignancies in patients
with refractory disease. The CARs developed thus far have
been directed against native cell-surface antigens, such as
CD19, that are recognized through antibody-derived anti-
gen-binding motifs, independent of antigen processing or
MHC-restricted presentation. However, tumor associated
intracellular self ags such as WT-1 require processing
following which antigenic epitopes are presented on the
tumor cell surface in complex with HLA class-I or class-II. A
strategy for targeting T-cells to speciﬁc peptide epitopes of
such self ags expressed on tumor cells involves genetically
introducing TCR mimic CARs containing a scFv ab directed
against the speciﬁc peptide-MHC complexes. CARs contain-
ing a Fab directed against an HLA-A0201-NY-ESO-1 epitope
have been generated, but functional data is lacking. We
generated a TCR-like CAR containing a scFv speciﬁc for an
HLA/peptide complex; the WT-1 RMFPNAPYL peptide pre-
sented by HLA-A0201 (A2-RMF CAR). The original A2-RMF
